Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis) – New orphan drug approvals
May 6, 2019 - The FDA announced the approval of Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Top